Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
NVO Stock: Should You Buy The Dip?
05:55am, Tuesday, 24'th Feb 2026
Novo Nordisk's stock dropped 16% on February 23rd after clinical trial results indicated that its experimental weight-loss medication, CagriSema, did not perform as well as Eli Lilly's competing drug,
374Water names Daniel Bogar as chief executive officer
05:07am, Tuesday, 24'th Feb 2026
374Water Inc (NASDAQ:SCWO, FRA:8LL) has announced a series of leadership changes to its executive team and board of directors as the company seeks to...
Brookmont Capital Management Buys 21,725 Shares of Novo Nordisk A/S $NVO
04:51am, Tuesday, 24'th Feb 2026
Brookmont Capital Management grew its stake in Novo Nordisk A/S (NYSE: NVO) by 38.0% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 78,858 shares of the com
Millennial Potash expands Banio Potash Project in Gabon with grant of exploration permit
04:36am, Tuesday, 24'th Feb 2026
Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF, FRA:XOD) announced that it has been granted the Haute Banio exploration permit in southern Gabon, expanding...
Analyst says he's thrown in the towel on Novo Nordisk after latest setback
04:12am, Tuesday, 24'th Feb 2026
Novo Nordisk's study showing a new drug wasn't as good as a rival's led one sell-side analyst to downgrade the stock for the first time in five years.
Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial
04:11am, Tuesday, 24'th Feb 2026
Novo Nordisk said an experimental obesity drug it is jointly developing with China's United Laboratories International Holdings helped patients lose weight in a midstage clinical trial in China.
Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss
03:50am, Tuesday, 24'th Feb 2026
Novo Nordisk said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss
Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
03:39am, Tuesday, 24'th Feb 2026
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese pe
Novo Nordisk A/S (NYSE:NVO) Sets New 52-Week Low After Analyst Downgrade
01:32am, Tuesday, 24'th Feb 2026
Novo Nordisk A/S (NYSE: NVO - Get Free Report)'s share price reached a new 52-week low during trading on Monday after Deutsche Bank Aktiengesellschaft downgraded the stock from a buy rating to a hold
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
12:09am, Tuesday, 24'th Feb 2026
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Dani
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
05:39pm, Monday, 23'rd Feb 2026
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
05:21pm, Monday, 23'rd Feb 2026
Expand NYSE: NVO Novo Nordisk Today's Change (-16.33%) $-7.75 Current Price $39.67 Key Data Points Market Cap $160B Day's Range $39.34 - $41.09 52wk Range $39.34 - $93.80 Volume 3.7M Avg Vol 21M Gross
Novo Nordisk Faces Setback as CagriSema Falls Short in Obesity Trial
02:14pm, Monday, 23'rd Feb 2026
Novo Nordisk (NVO) is experiencing a significant drop in stock value after its obesity drug candidate, CagriSema, failed to meet the primary endpoint in the RED
Novo Nordisk Shares Drop 15% After CagriSema Misses Phase 3 Goal
01:01pm, Monday, 23'rd Feb 2026
Novo Nordisk (NVO) shares came under heavy pressure Monday, falling more than 15% after the company's next-generation obesity therapy CagriSema delivered weaker
Novo Nordisk shares sink after weight loss drug fails to match Eli Lilly's in trial
12:12pm, Monday, 23'rd Feb 2026
Novo Nordisk stock fell Monday after it said its next-generation weight loss drug didn't meet its key goal of showing that it wasn't inferior to Eli Lilly's rival drug, in the latest blow to the Danis
